01/08/22 Health Advisory: CDC updated Antiviral Guidance; Booster Eligibility Expanded

tongue depressors and cotton swabs on physician's desk

COVID-19 Updates for Providers

Requested actions

Updated Antiviral Guidance

  • Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens the existing policy for booster doses in people 16–17 years old.
  • Offer COVID-19 vaccine booster doses to everyone 12 years or older least:
    • 5 months after completing Pfizer primary vaccine series.
    • 6 months after completing Moderna primary vaccine series.
    • 2 months after single dose of Johnson & Johnson vaccine.
    • Offer a third, additional dose of Pfizer (5 years or older) or Moderna (18 years or older) COVID-19 vaccine to people with compromised immune systems 28 days after receiving their second dose.


As Omicron cases surge in our region and healthcare system capacity is strained, we welcome news of additional tools to combat the pandemic and reduce the burden on our healthcare systems. We are working with community partners to establish equitable and accessible distribution of these therapeutics as they become available.

In the original clinical trial, sotrovimab treatment reduced the risk of the composite endpoints of hospitalization and death in high risk patients by 85%. Based on pre-print in vitro data, CDC currently believes sotrovimab is the only monoclonal antibody under EUA that retains efficacy against Omicron variant. Because sotrovimab supplies are limited—we expect to receive 550 doses for the entire state for the next month—it is imperative that we prioritize it for the highest risk individuals. See the risk tiers in CDC’s distribution plan for details.

We hope to have availability of oral antivirals very soon via local partner pharmacies for people in the middle tier high risk group. We plan to have detailed information to help providers access these medications as soon as they become available locally.

Additional information

COVID-19 vaccine

COVID-19 testing

COVID-19 therapeutics

Department of Health and Human Services (HHS) allocates monoclonal antibody and oral antiviral supplies to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapeutics. Email mcm@doh.wa.gov to register for HPoP training, held Tuesdays at 9 a.m.

COVID-19 prevention patient education

Share the following materials with patients.

Contacting the Health Department

360-778-6100        Main Call Line – available M-F 8:30am to 4:30pm

360-715-2588        Afterhours Answering Service – available after 4:30pm and weekends

360-778-6150        Communicable Disease Report Line – 24 hours a day 7 days a week

360-778-6103        Confidential Communicable Disease Fax – 24 hours a day 7 days a week

1500 N State Street, Bellingham WA 98225

Additional resources